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Abstract
Background & aims: A combination of infliximab and immunomodulators is the most efficacious treatment for Crohn's disease (CD). Patients have the best outcomes when their serum concentrations of these drugs are above a determined therapeutic threshold. We performed a prospective, randomized trial to determine whether therapeutic drug monitoring (TDM) to maintain serum levels of infliximab above 3 µg/mL produced higher rates of clinical and endoscopic remission than adapting dose based only on symptoms. 
Methods: We performed a double-blind trial in which 122 biologic-naïve adult patients with active CD (71 female, median age 29.8 years) received induction treatment with infliximab in combination with an immunosuppressant, from July 2012 through September 2015 at 27 centers in Europe. At week 14 of treatment, patients were randomly assigned (1:1:1) to 3 infliximab maintenance groups: dose increases (2 maximum) in steps of 2.5 mg/kg based on clinical symptoms and biomarker analysis and/or serum infliximab concentrations (dose intensification strategy [DIS]1 group); dose increase from 5 to 10 mg/kg based on the same criteria (DIS2 group); dose increase to 10 mg/kg based on clinical symptoms alone (controls). Patients' CD activity index scores, levels of C-reactive protein, fecal levels of calprotectin, and serum concentrations of infliximab were determined at baseline and at weeks 2, 4, 6, 12, and 14 of treatment, and then every 4 weeks thereafter until week 54. The primary endpoint was sustained corticosteroid-free clinical remission (CD activity index <150) from weeks 22 through 54 with no ulcers at week 54. 
Results: The primary endpoint was reached by 15 (33%) of 45 patients in the DIS1 group, 10 (27%) of 37 patients in the DIS2 group, and 16 (40%) of 40 patients in the control group (P = .50). 
Conclusions: In a prospective randomized exploratory trial of patients with active CD, we found increasing dose of infliximab based on a combination of symptoms, biomarkers, and serum drug concentrations does not lead to corticosteroid-free clinical remission in a larger proportion of patients than increasing dose based on symptoms alone. 
EUDRACT NUMBER: 2011-003038-14.
Keywords: Crohn's Disease; Therapeutic Drug Monitoring; Infliximab; Mucosal Healing.
Abbreviations used in this paper: CD, Crohn's disease; CDAI, Crohn's disease activity index; CDEIS, CD Endoscopic Index of Severity; CI, confidence interval; CRF, Case Record Form; CRP, C-reactive protein; DIS1, dose intensification strategy, IFX dose increase by increments of 2.5 mg/kg, maximally 2 times to a maximum dose of 10 mg/kg; DIS2, IFX dose increase by increments of 5 mg/kg, maximally 1 time, to a maximum dose of 10 mg/kg; ELISA, enzyme-linked immunosorbent assay; IFX, infliximab; GETAID, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives; TAILORIX, a randomized controlled trial investigating tailored treatment with infliximab for active luminal Crohn's disease; TDM, therapeutic drug monitoring; TL, trough level; TNF, tumor necrosis factor.
Editor's notes
Background and context : A combination of infliximab and immunomodulators is the most efficacious treatment for Crohn's disease (CD). Patients have the best outcomes when their serum concentrations of these drugs are above a determined therapeutic threshold.
New findings : Increasing dose of infliximab based on a combination of symptoms, biomarkers and serum drug concentrations does not lead to corticosteroid-free clinical remission in a larger proportion of patients than increasing dose based on symptoms alone.
Limitations : The study was not designed nor statistically powered to determine superiority of therapeutic drug monitoring (TDM).
Impact : These results could lead to further improvement of clinical trials and care for CD patients and further study of TDM.

Crohn's disease (CD) is a chronic destructive inflammatory disorder of the gastrointestinal tract, predominantly involving the distal small bowel and the colon. The condition often leads to bowel stenosis and/or fistulization, and most patients need to undergo surgery with resection of part of the bowel. The advent of tumor necrosis factor (TNF) inhibitors has been a major step forward in the treatment of CD. The best outcome has been observed in patients receiving combination treatment with infliximab (IFX) and azathioprine, compared with either drug alone, leading to clinical remission and healing of all ulcerations in 44% of the patients.1 Treatment effects were more pronounced in patients with evidence of ulcerations and elevated C-reactive protein (CRP) at baseline and in patients with a shorter disease history.1,2 In the "Step-Up vs Top-Down" trial that recruited patients with early CD, 73% of patients assigned to the top-down treatment algorithm (IFX induction followed by azathioprine maintenance) had absence of ulcerations at 2 years.3 Evidence is since accumulating that mucosal healing is associated with superior outcomes and reduction in the need for resection, and this endpoint has become a pivotal component of drug registration trials.4,5
Recently, evidence has been mounting that insufficient serum concentrations of anti-TNF agents and/or the development of antidrug antibodies impair clinical efficacy and mucosal healing and are associated with loss of response.6,7 In a post hoc analysis of the ACCENT-1 trial, sustained response to IFX was best predicted by a week 14 IFX serum concentration ≥3.5 µg/mL.8,9





The present trial ("a randomized controlled trial investigating tailored treatment with infliximab for active luminal Crohn's disease," TAILORIX) was a proof-of-concept randomized double-blind controlled study conducted in 27 centers from Belgium, France, and the Netherlands from July 2012 to September 2015. French, Belgian, and Dutch centers were affiliated with the Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). The trial was designed by investigators of the GETAID in conjunction with the sponsors (Merck Sharp Dome, Kenilworth, NJ and Johnson and Johnson, New Brunswick, NJ). Data were collected and analyzed by the GETAID. The study was approved by the local institutional review board of each participating center and by the French Health Authority (AFSSAPS) and was registered under Eudract number 2011-003038-14. Written informed consent was obtained from all participants.
Patients recruited were adults with active luminal CD naive to biologics with an indication to start anti-TNF therapy in accordance with national guidelines and reimbursement criteria. Disease activity was confirmed by a Crohn's disease activity index (CDAI) >220 with objective signs of active inflammation (high-sensitivity CRP >5 mg/L and/or fecal calprotectin >250 µg/g) and visible ulcers at baseline ileocolonoscopy. Patients with an imminent need for surgery, critical gastrointestinal stricture and obstructive symptoms, using corticosteroid therapy at doses >40 mg/d prednisolone or equivalent, active systemic infection, evidence of tuberculosis, usual contraindications to anti-TNF or immunosuppressants, or other serious concomitant diseases were excluded. Gastrointestinal infections were ruled out with fecal culture and an enzyme-linked immunosorbent assay (ELISA) for Clostridium difficile toxins.
Patients who were using azathioprine, mercaptopurine, or methotrexate at inclusion were instructed to continue these agents, whereas those naive to immunomodulators were started on azathioprine 2.0 to 2.5 mg/kg per day. The dose was reduced in case of toxicity or intolerance. If azathioprine was not tolerated, patients received methotrexate at a dose of 25 mg per week subcutaneously for 12 weeks followed by 15 mg subcutaneously per week in association with folic acid. Patients also intolerant to methotrexate received further IFX monotherapy. Patients taking oral corticosteroids at inclusion were instructed to follow a fixed tapering schedule aiming at complete corticosteroid withdrawal by week 14.
IFX was given intravenously at 5 mg/kg at weeks 0, 2, and 6 to all patients. Patients were randomized 1:1:1 at inclusion into 3 double-blind IFX maintenance regimens, administered every 8 weeks from week 14 to week 54 (end of the study period) as follows: IFX dose increase by increments of 2.5 mg/kg, maximally 2 times to a maximum dose of 10 mg/kg (DIS1) according to a prespecified algorithm (outlined later in this article), IFX dose increase by increments of 5 mg/kg, maximally 1 time, to a maximum dose of 10 mg/kg (DIS2) according to the same prespecified algorithm, IFX dose increase by 5 to 10 mg/kg if patients had a CDAI >220 at the current visit or a CDAI between 150 and 220 in the 2 weeks before the current visit in line with the registered label of IFX (control group). Dose increases were maintained for the rest of the trial. The prespecified algorithm prompted dose escalation in group DIS1 and DIS2 when 1 of the following criteria were met, in hierarchical order: (1) CDAI >220 (at the current visit) with an elevated serum CRP (>5 mg/L) and/or fecal calprotectin (>250 µg/g); (2) CDAI 150 to 220 for 2 consecutive weeks with an elevated CRP and/or fecal calprotectin; (3) IFX serum concentration at trough (TL) < 1 µg/mL at the previous measurement; (4) IFX TL 1-3 µg/mL at the previous measurement and 5) IFX TL 3 to 10 µg/mL with a drop by >50% compared with the week 14 IFX concentration. Importantly, a single additional IFX infusion at the 4-week interval was administered in case of TL < 1 µg/mL in patients in the 2 DIS groups, at a dose of 2.5 mg/kg in group DIS1 (maximally 2 times) or 5 mg/kg IFX in group DIS2 (maximally 1 time). No extra infusions were given to patients in the control group.
Randomization at week 0 was centrally performed online (ClinInfo, Lyon, France), balanced by permutation blocks the size of which was not disclosed to investigators, and stratified by center, and previous use of azathioprine, 6-mercaptopurine, or methotrexate.
Procedures
Study visits were scheduled at weeks —3 to —1, 0, 2, 4, 6, 12, and 14, and every 4 weeks thereafter until week 54. Patients' CDAI, CRP, fecal calprotectin, and IFX TL were determined at all the visits and entered by the site in an electronic Case Record Form (CRF). Serum CRP and safety laboratory tests were measured locally. Fecal calprotectin tests were done in duplicate at the sites using the Quantum Blue test (Buhlmann Laboratories, Schönenbuch, Switzerland). Serum samples for IFX concentrations were shipped to and measured at a single laboratory (KU Leuven, Leuven, Belgium) and the results were entered in the same CRF but remained invisible for the sites. IFX concentrations were measured using an in-house developed drug-sensitive ELISA assay as previously described.13 


The CRF automatically calculated the IFX dose to be given and forwarded this dose to the hospital pharmacies for preparation of the infusion but blinded for the investigators, study site staff, and patients. Antibodies to IFX were measured in all available serum samples after completion of the trial using a drug tolerant mobility shift assay by Prometheus Laboratories (San Diego, CA).
Patients underwent ileocolonoscopies at weeks 0,12, and 54. CD endoscopic activity was measured using the validated CD Endoscopic Index of Severity (CDEIS).14 Ileocolonoscopies were video recorded and scored by endoscopists who were blinded to patient identification and clinical data (GD, DL, LPB, FB).
Outcomes
The primary endpoint of the study was corticosteroid-free remission (CDAI <150) at all visits between week 22 and 54 associated with the absence of ulcers at week 54 and no surgery for bowel resection or abscess and no new fistula.
Prespecified secondary endpoints were the proportion of patients with no ulcers at weeks 12 and 54, clinical remission (CDAI <150) at each visit, sustained remission from week 14 onward, endoscopic remission (CDEIS < 3) at weeks 12 and 54, endoscopic response (decrease of CDEIS score of atleast 50%) at weeks 12 and 54, IFX dose increase during the study period, IFX TL >3 µg/mL between weeks 14 and 54, adverse events, total use of infliximab, need for resection, and new fistula or abscesses.
Sample Size Calculation
This was an exploratory study because no published data were available on which assumptions could be based. We estimated that in each arm approximately 30% of the patients would develop unmeasurable serum concentrations or be in need of dose increase within 1 year. By recruiting 40 patients in each arm, we assumed that at least 8 to 12 patients in each arm would need optimization, which would allow a sensible interpretation of the data.12
Statistical Analysis
All primary analyses were performed according to the intent-to-treat principle. Tabulated summary statistics are frequency (percentages) for discrete variables and medians (interquartile range) for continuous variables, unless otherwise specified.
Comparison of the primary endpoint (corticosteroid-free remission) across randomized groups was based on the exact Fisher test. Patients without available measures were considered as failures. Estimation of effect sizes was based on odds ratio estimated from a logistic regression model, adjusted for the stratifier (previous use of azathioprine).
Prevalence of sustained remission, or sustained IFX levels >3 µg/mL, all measured from week 14 onward, were estimated and compared by the exact Fisher test. Similar analyses were performed for analysis of new fistula or abscesses, and for need for resection. Comparison of clinical (CDAI), laboratory (high-sensitivity CRP, fecal calprotectin), and endoscopic status at all visits beyond week 14, were plotted, and then compared across randomized arms using mixed linear models for repeated observations. Patients undergoing surgical resection for CD were considered as failures on all the later end points.
All statistical tests were 2-sided, with P values of .05 or less denoting statistical significance. All analyses were performed on SAS 9.3 (SAS Inc, Cary, NC) or R 2.13.1 (http://www.R- (​http:​/​​/​www.R-​)project.org (​..​/​..​/​Downloads​/​project.org​)) statistical software. R packages survival and cmprsk were used.








Table 1. Patient Characteristics at Baseline
n (%)Median [interquartile range]	DIS1	DIS2	Control group
No. patients	45	37	40
Female sex	25 (56)	19 (51)	27 (68)
Age, y	29.1 (22.7-44.5)	30.2 (24.0-47.6)	28.7 (21.5-39.9)
CD duration, mo	4.8 (0.6-86.5)	12.2 (1.6-48.3)	6.2 (0.7-89.0)
CD location			
   Ileal	14 (31)	7 (19)	8 (20)
   Colonic	9 (20)	8 (22)	5 (13)
   Ileo-colonic	22 (49)	22 (59)	27 (67)
CD behavior			
   Nonstricturing nonpenetrating	33 (74)	27 (73)	30 (75)
   Stricturing	6 (13)	6 (16)	6 (15)
   Penetrating	6 (13)	4 (11)	4 (10)
Previous bowel surgery	2 (4)	5 (14)	5 (13)
Fistula	11 (24)	7 (19)	6 (15)
CDAI	265 (237-302)	289 (236-342)	287 (235-322)
CRP, mg/L	17 (7.8-34.3)	24 (9.4-75.0)	18.5 (6.8-36.3)
Fecal calprotectine, µg/g	1753 (736-1800)	1800 (926-1800)	1156 (543-1800)
CDEIS	11 (6.8-14.0)	10 (7.8-15.0)	9.9 (7.6-16.0)
Body weight, kg	63 [56.4;75]	70.25 [60.8;82.3]	61.0 [54.4;68.8]
Albumin, g/L	39 [34.3;43]	38.5 [33.6;41]	39.6 [36.3;42.5]

Early Dropout
Thirty-five (29%) of the patients dropped out of the trial before week 54: 13 (29%) of 45 in DIS1, 8 (22%) of 37 in DIS2, and 14 (35%) of 40 in the control group, after a median of 2.9, 4.6, and 5.8 months, respectively. The main reasons for dropout were lack of improvement (n = 17) and withdrawal of consent (n = 11) (Supplementary Figure 1).
Treatment
The cumulative incidence of first IFX intensification at the end of this 1-year trial was 44.4% (95% confidence interval [CI] 31.8-61.5) in DIS1, 62.2% (95% CI 46.1-78.3) in DIS2, and 40% (95% CI 24.4-55.5) in the control group (P = .47). Twelve (27%) of 45 patients received 2 dose escalations in DIS1 and additional interval infusions were given to 9 of 45 patients in DIS1 (2.5 mg/kg) and to 19 of 37 patients in DIS2 (5 mg/kg). The time to first dose escalation is demonstrated in Figure 1. The criteria, which triggered IFX dose escalation in the 3 groups, are given in Table 2. Interestingly, all patients who received dose intensification for symptomatic relapse in the control group (n = 16) had an elevated CRP and/or fecal calprotectin at dose escalation. As a matter of fact, only a minority of patients were dose escalated based on the serum concentrations.

Figure 1. Cumulative   incidence   of   the   first   IFX   dose intensification (dose escalation and/or additional infusion).

Endpoints
The primary endpoint (CDAI <150) between week 22 and 54 off glucocorticosteroids, without new fistula and surgery and without ulcers at the week 54 ileocolonoscopy was reached in 15 (33%) of 45, 10 (27%) of 37, and 16 (40%) of 40 patients in the DIS1, DIS2, and the control group, respectively (P = .50) (Figure 2A). The results of the DIS group 1 and 2 combined are shown in Supplementary Table 1.

Table 2.  Criteria That Triggered IFX Dose Escalation
n (%)	DIS1	DIS2	Control group
No. patients with dose escalation	20/45	23/37	16/40
CDAI >220	6 (30)a	6 (26)a	6 (38)
CDAI >150 x 2	3 (15)a	6 (26)a	9 (56)
IFX <1 µg/mL	3 (15)	4 (18)	0b
IFX 1-3 µg/mL	0	0	0b
IFX 3-10 µg/mL + 50% drop compared with week 14	2 (10)	3 (13)	0b
CDAI >220 + IFX <1 µg/mL	0	0	0b
CDAI >150 x 2 + IFX 3-10 µg/mL + 50% drop compared with week 14	0	0	0b
Other reasons	6 (30)	4 (17)	1 (6)
aWith CRP >5 mg/L and/or fecal calprotectin >250 µg/g.   bNo IFX concentrations were used in the control group.

At week 12, 16 (36%), 6 (16%), and 16 (40%) patients had no ulcerations on endoscopy in the DIS1, DIS2, and control groups (P = .054); by week 54, these proportions increased to 19 (42%), 20 (54%), and 20 (50%) patients, respectively (P = .56) (Figure 2B). Endoscopic remission (CDEIS <  3) was attained in 26 (58%), 13 (35%), and 15 (37.5%) patients in DIS1, DIS2, and the control group by week 12 (P = .070) and in 23 (51%), 19 (51%), and 21 (53%)   patients  by  week  54   (P  =   1.00)   (Figure  2C). Significant endoscopic improvement (CDEIS reduction >50%) was observed in 32 (71%), 24 (65%), and 26 (65%) patients by week 12 (P = .88), and in 28 (62%), 23 (62%), and 23 (57.5%) patients by week 54 (P = .89) (Figure 2D).
IFX Concentrations and Antibodies to IFX
A sustained IFX serum concentration >3 µg/mL between week 12 and 54 was observed in 21 (47%), 17 (46%), and 24 (60%) of the patients in DIS1, DIS2, and the control group, respectively (P = .38) (Figure 3). The mean concentrations in patients continuously above the 3 µg/mL cutoff was 7.8 ± 2.9 µg/mL, 9.3 ± 5.2 µg/mL, and 9.7 ± 4.5 µg/mL in DIS1, DIS2, and the control group, respectively, vs 3.6 ± 2.1 µg/mL, 4.3 ± 2.3 µg/mL, and 3.4 ± 2.3 µg/mL in patients not meeting that success criterion. Antibodies to IFX were measured at the end of the trial and were detected in 10 (22%), 6 (16%), and 5 (12.5%) patients in the DIS1, DIS2, and control groups.
Adverse Events




Figure 2. Primary endpoint and main secondary endpoints of the trial. (A) Proportion of patients in remission off glucocorticosteroids from week 22 to week 54, absence of ulcers at week 54, and no new fistula or surgery. (6) Proportion of patients with absence of ulcers at weeks 12 and 54. (C) Proportion of patients with CDEIS < 3 at weeks 12 and 54. (D) Proportion of patients with decrease of CDEIS >50% from inclusion at weeks 12 and 54.


Figure 3. Mean ± standard deviation of infliximab trough levels from 14 to 54 among the 3 groups.

Table 3. Serious Adverse Events and Adverse Events in the 3 Study Groups (Unrelated/Possibly Related/ Probably and Certainly Related)
	DIS1	DIS2	Control
Serious adverse events	14	14	11
  Gastrointestinal	9 (6/1/2)	6 (4/2/0)	6 (4/2/0)
    CD related	6 (4/1/1)	3 (3/0/0)	3 (0/1/0)
    Pancreatitis	1	2	2
    Bowel resection	1	1	2
    Gastrointestinal	2	0	0
        abscess			
  Infections	1 (0/0/1)	1 (0/1/0)	2 (2/0/0)
  Infusion reactions             (severe)	0	2	0
  Pregnancy	1	0	0
Adverse events	215	242	208
  Gastrointestinal	36 (34/1/1)	56 (43/13/0)	37 (26/3/8)
  Infections	60 (36/22/2)	61 (38/23/0)	48 (33/11/40)
  Musculoskeletal	24 (11/22/2)	21 (13/6/2)	23 (16/4/3)
  Neurological	30 (24/4/0)	23 (16/5/2)	26 (13/12/1)








In this prospective randomized trial, dose increase of IFX based on a combination of symptoms, biomarkers, and/or serum drug concentrations was not superior to dose increase based on symptoms alone. This is the first trial in which a biologic treatment for a chronic inflammatory disease is dose-adjusted immediately after induction treatment. Very stringent endpoints were used: symptomatic remission at all time points between weeks 22 and 54 with complete withdrawal of glucocorticosteroids, absence of new fistula and surgery, and absence of ulcerations at week 54 colonoscopy. In theory, this is the "ideal outcome" for patients receiving treatment for moderate to severe CD, where "mucosal healing" has become an established treatment target. Absence of ulcerations has been associated with a reduction of surgeries and hospitalizations and more favorable economic outcomes.2,4,5,15 The idea of a "TDM approach" is to prevent symptomatic relapse through dose intensification when serum concentrations of therapeutic antibody are becoming too low.
In the current trial, we implemented a dose-intensification strategy that was based on current clinical practice, that is, dose intensification if symptoms persist or recur with evidence of active inflammation using biomarkers and added the serum concentrations of IFX to the algorithm. Even in the absence of symptoms, patients received dose intensification or additional IFX infusions in the DIS groups. This approach is different from a so-called "tight control" strategy, where symptoms and biomarkers are measured at regular intervals and therapy is adjusted to induce and maintain remission. The "tight control" approach was recently found to be superior to usual care in the prospective CALM trial, although the criteria for symptom control were more stringent in the intervention arm (CDAI <150) than in the control group (CDAI <220).16
The most obvious reason for the different outcome in TAILORIX was the high incidence of dose intensification in the control group. Patients could increase their IFX dose only based on symptoms, and this knowledge may have encouraged patients and physicians to overreport symptoms prompting dose escalation. Of 43 dose-escalation opportunities based on CDAI in the DIS groups, 23 (53%) were avoided per protocol because the biomarkers were not elevated. In the control group, normal CRP and/or fecal calprotectin was observed in 9 (60%) of 15 of the CDAI-based dose-escalation events. Nonetheless, an overview of several cohorts treated with IFX for CD revealed dose intensification in approximately 30% of the patients.12 The findings in the current control group, therefore, seem to be in line with "routine care." However, despite a "proactive" dose-intensification schedule, the desired additional benefit of including IFX concentrations in the DIS was not observed in TAILORIX.
The therapeutic IFX serum-concentration threshold at trough that was selected for this trial was 3 µg/mL, which was based on retrospective evidence from the IFX registration trial ACCENT-1 and a number of observational cohort studies.9,17-19 ACCENT-1 was a trial in active CD in which patients who responded to a single infusion of IFX at 5 mg/kg received further systematic or episodic maintenance IFX infusions. Eighty-nine percent of the patients with elevated baseline CRP had normalization of their CRP, a reliable surrogate marker of disease control by week 14 if the IFX serum concentration was >2.2 µg/mL. Although there was considerable overlap in the IFX serum concentrations at every time point, they were on average twice as high in sustained responders vs in patients who lost response, and the median values in responders remained above 3 µg/mL. In another trial, Vande Casteele and colleagues11 randomized patients with inflammatory bowel disease in remission receiving maintenance treatment with IFX to dose adaptation based on symptoms vs serum concentrations at trough, using a "therapeutic window" of 3 to 7 µg/mL, and showed that the latter strategy was superior. Based on these observations, the cutoff IFX concentration of 3 µg/mL at trough was considered clinically relevant when this trial was initiated. However, 2 recent observational studies have suggested that clinical and biochemical remission rates are superior at higher median IFX concentrations.20,21 Given the wide variation in observed concentrations among responders, one may even wonder if the "therapeutic threshold" is identical for all patients and for the different phases of the treatment (ie, induction vs maintenance and active vs quiescent disease). The variability of the pharmacokinetics of infliximab among patients has so far been investigated poorly. Recent intensive pharmacokinetic studies during induction treatment for ulcerative colitis showed considerable interindividual variability of IFX clearance and intermediate levels reliably predicted lack of response.22
In the TAILORIX trial, serum concentrations of IFX were measured in samples collected immediately before the infusion (at "trough"). Because of shipment to a central laboratory and hence a delay of several days for the result to become available, the calculation of the IFX doses administered were based on the TL measured before the previous infusion. Although this practice corresponds to what is being done in clinical practice in centers in which TDM is used, the 8-week delay could be too long for certain patients to maintain their clinical response to treatment. Moreover, the DIS was applied only starting at week 14. This delay may have caused "missed opportunities" in the earliest phase of the treatment. Further research into the pharmacokinetics of this important induction phase is needed.
Forty percent of the patients in the control group (of whom 40% with dose escalation), 33% of patients in the DIS1 group (47% dose escalation), and 27% in the DIS2 group (62% dose escalation) met the primary endpoint of sustained steroid-free remission without ulcerations after 1 year of treatment. This means that only 24% of patients met the primary endpoint without dose intensification. Although this number appears low, it is in line with observations in ACCENT-1 where 29% of patients were in steroid-free remission at 54 weeks at 5 mg/kg IFX 8-weekly treatment, although no endoscopic data were systematically collected in this study. In the SONIC trial, steroid-free and ulcer-free remission at week 26 was observed in 44% of the patients randomized to combination treatment of IFX and azathio-prine. In this trial, the endpoint was evaluated as early as 6 months after randomization, and the CDAI was assessed at only 1 time point (and not serially, as in TAILORIX).

Dose adjustment in our study was applied in 1 direction only, namely dose increase and not dose reduction. Recent evidence suggests that once inflammation is under control and with full "target engagement," lower doses of anti-TNF agents may be sufficient to further control inflammation.23 This strategy, which has already found its implementation in the treatment of rheumatic diseases, could lead the way to a more favorable pharmaco-economic outcome.
Finally, the lack of any sample size computation should be mentioned, so that a lack of statistical power of the study is possible. Nevertheless, based on the study estimates across groups, any clinically meaningful dose effect appears unlikely.
In conclusion, dose increase of IFX for active CD based on a combination of symptoms, biomarkers, and serum concentrations was not superior to dose increase based on symptoms alone, although the study was not designed or powered to determine superiority of TDM. This trial underscores the difficulty to perform "pure TDM" trials when dose escalation of biologics is part of clinical practice.
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Supplementary Figure 1. Study fllowchart. SAE, serious adverse events.

Supplementary Table 1.Trial Results With Both TDM Groups Combined in Comparison to the Control Group
EndPoints	TDM1	TDM2	control group	P- value
	N = 45	%	N =37	%	N = 40	%	(1 + 2 vs 3)
Primary endpoint	15	33	10	27	16	40	0.31
No ulcer at week 12	16	36	6	16	16	40	0.20
No ulcer at week 54	19	42	20	54	20	50	0.30
Endoscopic remission at week 12	26	58	13	35	15	37.5	0.31
Endoscopic remission at week 54	23	51	19	51	21	53	0.40
Significant endoscopic improvement at week 12	32	71	24	65	26	65	1.00
Significant endoscopic improvement at week 54 (∆CDEIS>50%)	28	62	23	62	23	57.5	0.72




